AIM ImmunoTech (AIM) furnishes January 2026 corporate presentation with Ampligen focus

Rhea-AI Filing Summary

AIM ImmunoTech Inc. furnished its January 2026 Corporate Presentation as an exhibit to this report. The presentation is provided under Regulation FD to share updated corporate information with the market and is designated as “furnished,” meaning it is not treated as filed for certain liability purposes under federal securities laws.

The company reiterates that the presentation may contain forward-looking statements about its drug candidate Ampligen®, including current and anticipated future activities in viral diseases, cancers, and immune-deficiency disorders. AIM emphasizes that significant additional testing and human clinical trials are required, results from animal studies may not predict human outcomes, and there is no assurance that ongoing or planned clinical trials will be successful, yield favorable data, or proceed as expected. The company directs readers to the risk factors in its latest annual and quarterly reports for a fuller discussion of risks.

false 0000946644 0000946644 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 12, 2026

AIM IMMUNOTECH INC.

(Exact name of registrant as specified in its charter)

Delaware		001-27072		52-0845822
(state or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

2117 SW Highway 484, Ocala FL		34473
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (352) 448-7797

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.001 per share		AIM		NYSE American

Item 7.01. Regulation FD Disclosure.

Furnished herewith as Exhibit 99.1 is AIM’s January 2026 Corporate Presentation.

The information, including Exhibit 99.1 referenced herein, is “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, if and to the extent such subsequent filing specifically references the information herein as being incorporated by reference in such filing.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements included in the presentation filed herewith may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the presentation speak only as of the date of the presentation. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date thereof. We are in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and the presentation sets forth our current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, we cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the presentation. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. We cannot assure that our potential foreign operations will not be adversely affected by these risks.

Please review the “Risk Factors” section in our latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. Our filings are available at www.aimimmuno.com. The information found on our website is not incorporated by reference into this presentation and is included for reference purposes only.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are filed herewith:

Exhibit
Number		Description
99.1		“AIM January 2026 Corporate Presentation”
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AIM ImmunoTech Inc.
Date: January 12, 2026	By	/s/ Thomas K. Equels
		Thomas K. Equels, CEO

FAQ

What did AIM ImmunoTech (AIM) disclose in this 8-K filing?

AIM ImmunoTech furnished its January 2026 Corporate Presentation as Exhibit 99.1. The presentation provides updated corporate and program information and is being shared under Regulation FD.

Is the AIM January 2026 Corporate Presentation considered filed with the SEC?

No. AIM states that the presentation, including Exhibit 99.1, is “furnished” and not “filed” for purposes of Section 18 of the Exchange Act, which affects how related liabilities apply.

What forward-looking information does AIM highlight regarding Ampligen in this report?

The company notes that it is in various stages of determining whether Ampligen® will be effective in treating multiple viral diseases, cancers, and immune-deficiency disorders, and that the presentation describes its current and anticipated future activities.

What key risks and uncertainties does AIM ImmunoTech emphasize around Ampligen?

AIM explains that significant additional testing and human clinical trials are required, animal results may not predict human outcomes, and there is no assurance that current or planned trials will be successful, yield favorable data, or even proceed as expected due to factors such as regulatory approvals, drug supply, or changing institutional priorities.

Where does AIM ImmunoTech direct investors for more information on risks?

The company refers investors to the “Risk Factors” section in its latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, noting that its SEC filings are available at www.aimimmuno.com.

Does this 8-K report any new financial results or major transactions for AIM ImmunoTech?

No. This report focuses on furnishing the January 2026 Corporate Presentation and providing related forward-looking statement and risk disclosures, without presenting new financial results or major transactions.